This study evaluated micronuclei induction in peripheral T-lymphocytes after BNCT (boron neutron capture therapy) irradiation of 15 brain tumor and 20 head-and-neck cancer patients. In all of these patients, the micronucleus frequency increased after BNCT; the number of micronuclei per 1000 binucleated T-lymphocytes after BNCT increased by 33.0 ± 12.2 for brain tumor patients and 22.8 ± 10.3 for head-and-neck cancer patients. In 14 thyroid cancer patients who were administered radioiodine (3.3-5.6 GBq) treatment, the frequency of micronuclei after internal radioiodine therapy increased to 105.0 ± 30.5 per 1000 binucleated T-lymphocytes. The increased micronucleus frequency of BNCT patients was less than one-third that seen for thyroid cancer patients after radioiodine treatment. These results demonstrate the usefulness of BNCT for selective high-LET radiotherapy, in association with a low irradiation effect of cytological radiation damage after BNCT, which provides a high tumor target dose for each cancer patient.
INTRODUCTION
The principle underlying boron neutron capture therapy (BNCT) is the efficient destruction of tumor cells by the 10 B(n,α) 7 Li reaction. Accumulation of 10 B in the target tumor and delivery of an effective dose of thermal neutrons at target depth promotes tumor cell death. An alpha particle and a recoiling 7 Li ion, possessing an average total kinetic energy of 2.34 MeV, are released when tumor cells that have accumulated sufficient boron compounds are exposed to thermal neutrons. These particles have the characteristics of high linear energy transfer (LET) radiation with enhanced biological effects. The relative biological effectiveness (RBE) of cell killing and mutation frequency increase with high-LET radiation. Thus, BNCT patients suffer little damage to normal tissue, which takes up boron compounds less efficiently than the tumor despite the high tumor dose. While we always monitor total body radiation dose by neutron fluence and thermoluminescent dosimeter (TLD) estimation, the cytological effect of neutron radiation after BNCT has not previously been studied in detail.
Radioiodine therapy for thyroid cancer patients is the global standard of care. 1) Many biomonitoring studies of thyroid cancer patients after radioiodine administration have assessed chromosomal damage in lymphocytes, 2, 3) lymphocyte-micronuclei, 4, 5) and reticulocyte-micronuclei, 6) and have directly monitored blood vessels. 7) Radioiodine therapy is a form of internal-irradiation using the 131 I radioisotope, which release beta-particles. In contrast, BNCT is a binary radiotherapy modality that combines a stable isotope of boron ( 10 B), which releases alpha-paticles, and a beam of low energy neutrons. Both radioiodine therapy and BNCT have the radiation effect on target tumors of high-dose irradiation of the tumor, with a minimal effect on the surrounding normal tissue cells.
Micronucleus assays can assess cytogenetic damage by simple and convenient techniques following occupational, therapeutic, and accidental exposures to radiation. In conventional radiotherapy, many researchers investigated cytogenetic damage following radiation using the micronucleus assay. [8] [9] [10] In this study, we examined the frequency of lymphocyte micronuclei in patients before and after BNCT and evaluated the cytological radiation damage in BNCT patients in comparison to that seen in thyroid cancer patients before and after radioiodine therapy.
MATERIALS AND METHODS

BNCT patients and BNCT therapy
From June 2003 to December 2005, peripheral blood samples were obtained from 35 cancer patients, of which 20 had head-and-neck cancers and 15 had brain tumors. The clinical characteristics of each patient, including age, sex, previous radiotherapy and chemotherapy, are shown in Table  1 . BNCT information for each patient, including radiation tumor dose, radiation time, and concentration of boron given, are shown in Table 2 . Written informed consent was obtained from all patients.
The heavy water column of the Kyoto University
Research Reactor (KUR), remodeled in May 1996, is used for neutron capture therapy. To control the neutron energy spectrum for an epithermal neutron enhancement region of AL 80%/D2O 20%, a spectrum shifter (D2O) and thermal neutron filters (alloy of boron/aluminum and cadmium) were employed at the updated facility. Neutron irradiation is performed by controlling the heavy water thickness of the spectrum shifter and employing thermal neutron filters of boron/ aluminum with varying cadmium ratios. 11, 12) The boron compounds used in BNCT were borocaptate sodium (BSH) and para-boronophenylalanine (BPA). Both BSH and BPA were used for treatment of the brain tumor patients, while the head-and-neck tumor patients were treated according to the following protocol. Five grams of BSH, dissolved in 50% physiological saline, were infused intravenously over one hour. BPA was dissolved in DDW by the Table  2 .
Blood samples from BNCT patients were collected in heparinized tubes before and 30-40 minutes after neutron irradiation. We measured the neutron fluences and gamma ray doses to estimate the total body absorbed dose. Thermal neutron fluences were measured by coiled gold wire (0.25 mm diameter; 10 cm length) activation analysis. Gamma ray doses, including secondary capture gamma rays, were measured with a BeO; TLD (thermo-luminescence) dosimeter. We made measurements with the gold wire and TLD at seven points on the body, the surface of the tumor lesion, neck, breast, middle abdomen, groin, knee, and foot. The total absorbed dose resulting from thermal neutron irradiation was calculated as the sum of the absorbed doses, primarily from the neutron reactions and gamma ray dose. The detailed method of calculation for the neutron dose has been described previously. [13] [14] [15] [16] The effective dose was calculated according to the technical guide for the estimation of a uniform equivalent dose over the whole body as detailed by the Japanese Radiation Council held in Japan on Aug. 21, 2000: 17) HEE = 0.08Ha + 0.44Hb + 0.45Hc + 0.03Hm in which HEE is the equivalent dose in external radiation for the whole body, Ha is the equivalent dose in external radiation for the head and neck, Hb is the equivalent dose in external radiation for the upper abdomen, Hc is the equivalent dose in external radiation for the lower abdomen, and Hm is the equivalent dose in external radiation for the maxim (tumor lesion).
Each coefficient factor followed tissue weighting factors provided in the 1990 Recommendations of the ICRP.
18)
Thyroid cancer patients for radioiodine treatment
Peripheral blood samples were obtained from 14 thyroid cancer patients before and seven days after radioiodine treatment. Patients were admitted for radioiodine treatment of differentiated thyroid carcinoma with lung, bone, or liver metastasis at the Department of Radiology and Nuclear Medicine of Kyoto University in Japan. The clinical characteristics of each patient, including age, sex, and previous radiotherapy, are shown in Table 1 . Informed consent was obtained from all patients.
Irradiation in Vitro
Blood samples taken before BNCT and radioiodine administration were irradiated at room temperature prior to the addition of PHA. For irradiation, the 60 Co γ-ray machine delivered radiation at a rate of 1.0 Gy/min. Samples were placed in a plastic box filled with water to allow for full dose build-up.
Cytokinesis-block micronucleus assay of lymphocytes
Cytokinesis-block micronucleus assay of lymphocytes was performed according to the method outlined by Fenech and Morley. 19) Cytochalasin B (Sigma), dissolved in dimethyl sulfoxide at a concentration of 1 mg/ml, was stored at -80°C. This stock solution was thawed, diluted in saline, and added at a final concentration of 5.0 μg/ml to cultures 44 hours after PHA stimulation. Eighteen hours after addition of cytochalasin B, cells were collected by centrifugation for 5 min at 1000 × G. A drop of the cell suspension was spread on a glass slide and dried. After staining the cells with ethidium bromide (20 μg/ml), the frequency of micronuclei was determined the total number of micronuclei in 1000 cytochalasin B-blocked binucleated cells (CB). Micronuclei were identified according to published criteria. 19, 22) 
Statistical analysis
Statistical significance was calculated using the MannWhitney's U test. Differences were considered significant at P < 0.05. 
RESULTS
The total effective doses of BNCT, determined by thermal neutron fluence and TLD estimation, are shown in Fig. 1 . The total body dose rates for head and neck cancer and brain tumor patients were 0.35 cGy/min (Fig. 1A) and 0.38 cGy/ min (Fig. 1B) , respectively. There were no significant differences in equivalent doses in external radiation for the whole body determined by thermal neutron fluence and TLD estimation between head and neck cancer patients and brain tumor patients.
The micronucleus yields per 1000 binucleate cells for peripheral T-lymphocytes before and after BNCT radiation are shown in Fig. 2 and Table 3 . The number of micronuclei per 1000 CB after BNCT increased by 22.8 ± 10.3 in headand-neck cancer patients and 33.0 ± 12.2 in the brain tumor patients after BNCT.
The micronucleus yields per 1000 CB cells among peripheral T-lymphocytes before and after radioiodine treatment for thyroid cancer patients ( Fig. 2 and Table 4 ) demonstrated that the number of micronuclei per 1000 CB after radioiodine administration increased by 105.0 ± 30.5 in thyroid cancer patients.
We determined the number of micronuclei per 1000 CB cells after in vitro irradiation at absorbed doses of 0.5 and 1.0 Gy (Table 5 ). Linear models were used to fit the doseresponse relationship (lower part of Table 5 ). Based on the dose-response relationship and the observed frequency of micronuclei in vivo, we estimated the absorbed doses at 0.21 ± 0.09Gy in head-and-neck cancer patients and 0.28 ± 0.10 Gy in brain tumor patients after BNCT and 0.83 ± 0.24 Gy in thyroid cancer patients after radioiodine treatment.
DISCUSSION
After the remodeling of our KUR heavy water thermal neutron irradiation facility, utilization of epithermal neutron irradiation for the treatment of deep-seated tumors has contributed considerably to the success of BNCT treatment of brain tumors. With the aim of widening the application of BNCT to additional cancers, we began using BNCT for head-and-neck cancer patients in the 2001. With the adaptation of BNCT to head-and-neck cancers 20) and liver and lung malignancies, biological dosimetry to evaluate cytological radiation damage secondary to BNCT is required in addition to monitoring the physiologic external radiation doses.
In this study, we confirmed the external radiation doses (0.35-0.38 cGy/min) provided by BNCT using gold wire activation and TLD dosimetry. These results are compatible with the absorbed doses measured by phantom-experiments. 21) The total effective dose of BNCT, calculated by thermal neutron fluency and TLD estimation, indicated that the total body radiation dose was slightly higher in headand-neck cancer patients than in brain tumor patients, despite a lower tumor dose of head-and-neck cancer patients. Thus, the total body dose estimation may be affected by the position of neutron irradiation. Neutrons emitted from the KUR reactor in a horizontal beam; head-and-neck cancer patients were irradiated in a sitting position, in which the neck lesions were closer to the neutron beam source than the lesions of brain tumor patients.
The peripheral blood lymphocytes MN assay was first developed by Countryman and Heddle. 22) Fenech and Morley later revealed that the cytokinesis-blocked MN (CBMN) assay was able to score MN in dividing cells by recognizing their binucleate appearance. 19) This method is a simple and convenient technique that serves to study the genetic risk following occupational, therapeutic, or accidental radiation exposures. In radiotherapy studies of cancer patients, the lymphocyte micronucleus assay serves as a valuable in vivo biodosimeter. 23) Prior studies reported that a cancer patient population exhibited a variable baseline frequency of micronuclei; radiation-induced increases in micronucleus frequency appeared to be significantly affected by prior chemotherapy and radiotherapy sessions. 24, 25) We recorded the clinical histories of BNCT patients, documenting previous chemotherapy and radiotherapy treatments. A large percentage of BNCT patients had received prior radiotherapy or chemotherapy; a large proportion of the thyroid cancer patients had also received prior radiotherapy. These diverse clinical histories negatively affected the high yield of baseline micronucleus frequency in these patients. The dose-response frequency of micronuclei yield in the in vitro irradiation study, however, did not vary in BNCT patients or thyroid cancer patients in comparison with healthy volunteers.
Previous researchers have estimated the cytological effects of large therapeutic doses of radioiodine therapy in patients with thyroid cancer. 5, 7, 26, 27) Using the lymphocyte MN assay, their estimated dose was approximately 0.33-0.54 Gy following administration of 3.7 GBq of 131 I. 5) In our study of radioiodine therapy, the administration dose varied from 3.4-5.6 GBq. The corrected micronucleus induction at 3.7 GBq of 131 I was 88.7 ± 21.7 per 1000 CB cells, with the assumption that micronucleus induction would increase with increasing 131 I administration in a dose-dependent manner (Fig. 3) . The absorbed doses were 0.68 ± 0.17 Gy for thyroid cancer patients after 3.7 GBq of radioiodine, based on the dose-response relationship and the observed frequency of micronuclei in vivo. The difference between the absorbed and expected doses in radioiodine therapy suggests that calibration based on high-dose-rate external radiation exposure in vitro underestimates the dose given. 28) After BNCT, the numbers of micronuclei per 1000 binucleated T-lymphocytes increased by 33.0 ± 12.2 for brain tumor patients and 22.8 ± 10.3 for head-and-neck cancer patients. The increase in micronucleus frequency after BNCT was approximately one-third that of micronuclei induced by 3.7 GBq 131 I administration in thyroid cancer patients. The absorbed dose was estimated at 0.28 ± 0.10 Gy for brain tumor patients, 0.21 ± 0.09Gy for head-and-neck cancer patients after BNCT, and 0.68 ± 0.17 Gy for thyroid cancer patients after treatment with 3.7 GBq radioiodine. The absorbed dose after BNCT was estimated to be approximately 30-40% of the absorbed dose after 3.7 GBq 131 I administrations in thyroid cancer patients. As assessed by micronucleus assay, the estimated radiation doses in BNCTtreated patients were similar to the total effective doses of BNCT determined by thermal neutron fluence and TLD estimation, confirming that there is no effect of a dose component of the 10 B(n,α) 7 Li reaction on non-tumor-specific boron in normal tissues.
In conventional radiotherapy, a number of researchers have examined the usefulness of the micronucleus assay of lymphocytes as a biological dosimetry method. 9, 29) Recently, Minicucci et al. reported the MN frequencies of lymphocytes in head-and-neck cancer patients undergoing radiotherapy. 30) In that study, the post-radiation micronucleus induction increased ten-fold in comparison to before-radiation controls at tumor doses of 45-70 Gy and a mean equivalent body radiation dose of 6.2Gy. In our study, post-BNCT micronucleus induction increased 1.4-fold in the head-andneck cancer patients and 1.6-fold higher in the brain tumor patients in comparison to pre-BNCT levels.
In conclusion, our study demonstrated that BNCT results in a low irradiation effect on the total body and a low cytological effect despite the high tumor target dose. Thus, BNCT is efficient and selective high-LET radiotherapy method with little damage to normal tissues. 
